PTPI - Petros Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers - Specialty & Generic
New York,
United States
Type: Equity
PTPI price evolution
PTPI
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.46 | $11.08 | $13.34 | $17.97 |
| Short term investments | ||||
| Net receivables | $1.78 | $1.96 | $2.23 | $2.98 |
| Inventory | $2.85 | $2.74 | $2.79 | $2.5 |
| Total current assets | $13.98 | $17.9 | $20.39 | $24.43 |
| Long term investments | ||||
| Property, plant & equipment | $0.18 | $0.22 | $0.26 | $0.29 |
| Goodwill & intangible assets | $7.54 | $8.26 | $8.97 | $9.77 |
| Total noncurrent assets | $11.19 | $12.41 | $13.41 | $14.48 |
| Total investments | ||||
| Total assets | $25.17 | $30.31 | $33.8 | $38.91 |
| Current liabilities | ||||
| Accounts payable | $0.79 | $2.14 | $1.71 | $1.36 |
| Deferred revenue | ||||
| Short long term debt | $1.94 | $1.55 | $1.16 | $1.14 |
| Total current liabilities | $9.98 | $11.22 | $10.77 | $8.08 |
| Long term debt | $5.7 | $6.46 | $6.86 | $7.25 |
| Total noncurrent liabilities | $6.01 | $8.4 | $10.55 | $23.78 |
| Total debt | $7.63 | $8.01 | $8.01 | $8.39 |
| Total liabilities | $15.98 | $19.62 | $21.32 | $31.86 |
| Shareholders' equity | ||||
| Retained earnings | -$101.71 | -$101.05 | -$98.89 | -$99.21 |
| Other shareholder equity | ||||
| Total shareholder equity | $8.07 | $9.79 | $12.07 | $6.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.34 | $9.43 | $23.85 | $17.14 |
| Short term investments | ||||
| Net receivables | $2.23 | $2.11 | $2.46 | $5.15 |
| Inventory | $2.79 | $1.82 | $0.52 | $0.76 |
| Total current assets | $20.39 | $14.67 | $30.54 | $25.91 |
| Long term investments | ||||
| Property, plant & equipment | $0.26 | $0.04 | $0.05 | $0.06 |
| Goodwill & intangible assets | $8.97 | $12.24 | $25.29 | $32.16 |
| Total noncurrent assets | $13.41 | $17.75 | $36.85 | $43.95 |
| Total investments | ||||
| Total assets | $33.8 | $32.42 | $67.39 | $69.85 |
| Current liabilities | ||||
| Accounts payable | $1.71 | $1.81 | $4.56 | $5.61 |
| Deferred revenue | ||||
| Short long term debt | $1.16 | $1.09 | $7.18 | |
| Total current liabilities | $10.77 | $7.07 | $30.98 | $41.89 |
| Long term debt | $6.86 | $8.39 | ||
| Total noncurrent liabilities | $10.55 | $8.65 | $0.87 | $10.49 |
| Total debt | $8.01 | $9.48 | $7.18 | |
| Total liabilities | $21.32 | $15.72 | $31.85 | $52.38 |
| Shareholders' equity | ||||
| Retained earnings | -$98.89 | -$90.73 | -$70.69 | -$61.7 |
| Other shareholder equity | ||||
| Total shareholder equity | $12.07 | $16.7 | $35.54 | $17.47 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.42 | $1.39 | -$0.36 | $1.67 |
| Cost of revenue | $0.33 | $0.33 | $0.16 | $0.41 |
| Gross Profit | $1.09 | $1.06 | -$0.52 | $1.27 |
| Operating activities | ||||
| Research & development | $0.37 | $1.56 | $0.83 | $0.39 |
| Selling, general & administrative | $2.29 | $2.71 | $2.88 | $2 |
| Total operating expenses | $3.37 | $4.99 | $4.52 | $3.22 |
| Operating income | -$2.28 | -$3.93 | -$5.04 | -$1.95 |
| Income from continuing operations | ||||
| EBIT | -$0.55 | -$2.04 | $0.44 | -$4.42 |
| Income tax expense | ||||
| Interest expense | $0.11 | $0.12 | $0.13 | $0.13 |
| Net income | ||||
| Net income | -$0.66 | -$2.16 | $0.32 | -$4.55 |
| Income (for common shares) | -$2.73 | -$8.03 | -$4.99 | -$4.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.82 | $5.99 | $7.81 | $9.56 |
| Cost of revenue | $1.63 | $2.29 | $1.6 | $4.05 |
| Gross Profit | $4.19 | $3.7 | $6.21 | $5.51 |
| Operating activities | ||||
| Research & development | $2.41 | $1.74 | $1.79 | $0.46 |
| Selling, general & administrative | $9.26 | $12.21 | $15.59 | $15.67 |
| Total operating expenses | $14.95 | $23.62 | $24.26 | $22.8 |
| Operating income | -$10.76 | -$19.92 | -$18.05 | -$17.28 |
| Income from continuing operations | ||||
| EBIT | -$7.63 | -$19.44 | -$8.62 | -$18.96 |
| Income tax expense | -$1.43 | |||
| Interest expense | $0.54 | $0.6 | $0.37 | $3.05 |
| Net income | ||||
| Net income | -$8.16 | -$20.04 | -$8.99 | -$20.59 |
| Income (for common shares) | -$13.81 | -$20.04 | -$8.99 | -$20.59 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$0.66 | -$2.16 | $0.32 | -$4.55 |
| Operating activities | ||||
| Depreciation | $0.75 | $0.75 | $0.84 | $0.86 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.12 | $0.29 | $0.21 | $0.03 |
| Total cash flows from operations | -$1.66 | -$1.13 | -$2.26 | -$4.05 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15 | |||
| Net borrowings | -$0.38 | -$0.37 | -$0.37 | |
| Total cash flows from financing | -$1.96 | -$1.12 | -$2.37 | $14.63 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.62 | -$2.26 | -$4.63 | $10.59 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$8.16 | -$20.04 | -$8.99 | -$20.59 |
| Operating activities | ||||
| Depreciation | $3.42 | $5.72 | $6.98 | $6.75 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.42 | $1.2 | $1.31 | |
| Total cash flows from operations | -$7.63 | -$12.8 | -$11.86 | -$15.31 |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | ||||
| Total cash flows from investing | -$0 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15 | $25.76 | $21.57 | |
| Net borrowings | -$1.46 | -$1.62 | -$7.19 | $8.73 |
| Total cash flows from financing | $11.54 | -$1.62 | $18.57 | $30.3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.91 | -$14.42 | $6.71 | $14.99 |
News
|
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED...
Benzinga · via Yahoo Finance
21 Jun 2024
|
|
80 Biggest Movers From Yesterday
Benzinga via Yahoo Finance
17 Nov 2021
|
|
36 Stocks Moving in Tuesday's Pre-Market Session
Benzinga via Yahoo Finance
16 Nov 2021
|
|
81 Biggest Movers From Yesterday
Benzinga via Yahoo Finance
5 Nov 2021
|
|
55 Stocks Moving In Thursday's Mid-Day Session
Benzinga via Yahoo Finance
4 Nov 2021
|
|
24 Stocks Moving in Thursday's Pre-Market Session
Benzinga via Yahoo Finance
27 Oct 2021
|
|
Why Petros Pharmaceuticals Stock Is Soaring Today
Benzinga via Yahoo Finance
20 Oct 2021
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $4.12M |
|---|---|
| EBITDA | -$3.36M |
| EBIT | -$6.56M |
| Net Income | -$7.06M |
| Revenue Q/Q | -28.71% |
| Revenue Y/Y | 6.97% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -22.02% |
| ROE | -76.57% |
| Debt/Equity | 1.77 |
|---|---|
| Net debt/EBITDA | -2.54 |
| Current ratio | 1.40 |
| Quick ratio | 1.12 |